Stock listing

Munich:BO1 BioCryst Pharmaceuticals, Inc. Aktie

German listing (Munich) of BioCryst Pharmaceuticals, Inc. · home listing NASDAQ:BCRX

Follow BioCryst Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · MUN:BO1

€7.08 EUR +0.16 (+2.3%)

Close on Oct 27, 2026

Day range
€7.08 – €7.08 EUROct 27, 2026
Market cap
€1.82B EURAt the close on Oct 27, 2026 · price × 257.4M shares outstanding
BioCryst Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BCRX · Home$8.245 USD-0.225 (-2.7%)4,090,264$8.49$8.52$8.22$8.47Close on Nov 2, 2026
Frankfurt:BO1€7.244 EUR+0.422 (+6.2%)—€6.98€7.244€6.98€6.822Close on Oct 27, 2026
Munich:BO1€7.076 EUR+0.16 (+2.3%)—€7.076€7.078€7.076€6.916Close on Oct 27, 2026
Ticker
Munich:BO1
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Calls

Upcoming

  • Biocryst Pharmaceuticals (NASDAQ:BCRX) Q3 2026 Earnings Call

    Wed, Nov 04, 2026 · 8:30 AM ET

    Register

Replays

  • Biocryst Pharmaceuticals (NASDAQ:BCRX) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 8:30 AM ET

    Watch Transcript

  • Biocryst Pharmaceuticals (NASDAQ:BCRX) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 8:30 AM ET

    Watch Transcript

  • Biocryst Pharmaceuticals (NASDAQ:BCRX) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Oct 29, 2026

BioCryst to Report Third Quarter 2026 Financial Results on November 4

Oct 21, 2026

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

Oct 21, 2026

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

Oct 5, 2026

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

Aug 25, 2026

BioCryst Reports Second Quarter 2026 Financial Results

Aug 5, 2026

BioCryst to Report Second Quarter 2026 Financial Results on August 5

Jul 22, 2026

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

Jul 15, 2026

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

Jun 29, 2026

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

Jun 12, 2026

All BioCryst Pharmaceuticals, Inc. news

Decks

BioCryst Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
30 in the last 12 months · 220 in all · newest Oct 29, 2026 · oldest 2019
Calls
24 calls with a replay · 24 with a transcript · latest Aug 5, 2026
Decks
36 decks · latest May 6, 2026

Where BioCryst Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BCRX · Home listingNASDAQUnited StatesUSD
Tradegate:BO1TradegateGermanyEUR
gettex:BO1gettexGermanyEUR
LS Exchange:896047LS ExchangeGermanyEUR
BMV:BCRXBMVMexicoMXN
Lang & Schwarz:896047Lang & SchwarzGermanyEUR
Frankfurt:BO1FrankfurtGermanyEUR
BIVA:BCRXBIVAMexicoMXN
BOATS:BCRXBOATSUnited StatesUSD
Stuttgart:BO1StuttgartGermanyEUR
Dusseldorf:BO1DusseldorfGermanyEUR
Munich:BO1 · This pageMunichGermanyEUR
BX Swiss:BO1BX SwissSwitzerlandCHF

Log in to ask 6ix AI your own questions about BioCryst Pharmaceuticals, Inc.